Cytokinetics (NASDAQ: CYTK) shares rocketed 28% Tuesday after the company reported positive topline results from ACACIA-HCM, the pivotal Phase 3 clinical trial evaluating aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (HCM). The strong data position the cardiac biotech to potentially expand its already-approved therapy into a patient population with no currently approved treatment options.
Trial Hits Both Primary Endpoints
The ACACIA-HCM trial cleared both of its dual primary endpoints, delivering statistically significant improvements from baseline to Week 36 compared to placebo. Specifically, the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) showed a 3.0-point difference between aficamten and placebo (p=0.021). Meanwhile, maximal exercise performance, measured by pVO2, demonstrated a difference of 0.67 mL/kg/min (p=0.003).
The study randomized and treated 516 participants on a 1:1 basis with either aficamten or placebo. Beyond the primary endpoints, the trial also delivered statistically significant improvements across key secondary measures — most notably, the proportion of participants achieving at least one class improvement in New York Heart Association (NYHA) functional class.
A First-of-Its-Kind Result for Non-Obstructive HCM
For patients living with non-obstructive HCM, the data carry particular weight. “Patients with non-obstructive HCM have no therapies approved to treat the underlying hypercontractility associated with the disease,” said Fady I. Malik, Cytokinetics’ Executive Vice President of Research & Development. “We hope that will change with ACACIA-HCM, which is the first clinical trial to demonstrate statistically significant improvements in exercise capacity and symptom burden in patients with non-obstructive HCM.”
In other words, the trial doesn’t just clear a regulatory bar — it establishes a clinical first in a disease area where physicians have long lacked targeted therapies.
Clean Safety Profile
Equally important, the trial surfaced no new safety signals. Furthermore, dosing completion rates tracked closely between the two arms, with 88.4% of aficamten-treated patients completing planned dosing compared to 90.3% on placebo. Consequently, the safety and tolerability profile appears consistent with prior aficamten studies.
Building on an Approved Foundation
Aficamten already enjoys approval in the U.S., China, and European Union under the brand name MYQORZO for the treatment of symptomatic obstructive hypertrophic cardiomyopathy. With the ACACIA-HCM readout, however, Cytokinetics now has a clear pathway to potentially broaden the drug’s label into the non-obstructive HCM population — significantly expanding its addressable market.
Looking ahead, the company plans to present detailed trial results at an upcoming medical meeting. In addition, Cytokinetics will discuss the findings with the FDA and other regulatory authorities to chart the next steps toward a potential label expansion.
The combination of statistically significant efficacy on both primary endpoints, a clean safety profile, and a clear regulatory path forward helps explain why investors moved decisively on the news, sending CYTK shares sharply higher.
For more investor relations infomation on Cytokinetics pleased visit www.invest.cytonics.com.
The post Cytokinetics Stock Soars 28% on Positive Phase 3 ACACIA-HCM Trial Results appeared first on PRISM MarketView.